Polyclonal TLR7 (IN)
- Known as:
- Polyclonal TLR7 (IN)
- Catalog number:
- pc-446
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Kamiya biomedical company
- Gene target:
- Polyclonal TLR7 ()
Related genes to: Polyclonal TLR7 (IN)
- Gene:
- TLR7 NIH gene
- Name:
- toll like receptor 7
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- Xp22.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-04-27
- Date modifiied:
- 2016-10-05
Related products to: Polyclonal TLR7 (IN)
Related articles to: Polyclonal TLR7 (IN)
- Toll-like receptors (TLRs) are essential in the innate immune response. Furthermore, neuronal TLRs have been involved in regulating neuronal dendritic outgrowth and excitability. However, a deeper understanding of neuronal-TLR function is essential. We investigated the expression and role of TLR8 using mouse postnatal hippocampal neuronal cultures. We assessed TLR8 (and TLR7) expression by immunocytochemistry and TLR8 functionality via electrophysiological recordings in a high-density multi-electrode array system and calcium flux imaging. Pathway activation following fast TLR8 stimulation was performed via Western blot. TLR8 and TLR7 are expressed in postnatal hippocampal neurons at DIV14 and in neurosphere-derived neurons. TLR8 expression was detected in the cell body and dendrites of GABAergic, parvalbumin-expressing interneurons. Stimulation with the TLR8 agonist TL8-506 led to increased neuronal activity in the short term and enhanced neuronal synchronization in short- and long-term recordings. The calcium flux induced by TLR8 was reduced by blocking NMDA receptors with D-AP5. TLR8 stimulation did not lead to IkB-α degradation. Our findings demonstrate that TLR8 and TLR7 are expressed in mouse postnatal hippocampal neurons. TLR8 activation leads to increased neuronal excitability that was decreased by NMDA antagonism. However, acute TLR8 stimulation failed to robustly activate the canonical TLR signaling pathway. We propose that TLR8 activation might lead to the enhancement of excitatory NMDA receptors. - Source: PubMed
Publication date: 2026/07/13
Fenkart JulianSantagostino AliceSeidlberger StephanieSchmuck ArminDonat KatharinaDrexel MeinradSantos-Sierra Sandra - Anthralin has a long history as a topical treatment for psoriasis, where it reduces keratinocyte hyper-proliferation and effectively clears plaques. While it lowers inflammatory markers in psoriatic skin, it paradoxically induces inflammation in healthy skin through reactive oxygen species (ROS) and related pathways. However, its precise mechanism of action remains incompletely understood. Interestingly, the once undesirable pro-inflammatory effect in healthy skin may now represent a valuable adjuvant property for transcutaneous immunization (TCI). In particular, combining anthralin with the TLR7 agonist imiquimod (IMQ) elicits strong cytotoxic T-cell responses in pre-clinical studies. When paired with antigenic peptides that can penetrate the skin, this immunization approach is especially promising in the context of cancer therapy, given the central role of cytotoxic T-cells in tumor rejection. However, current evidence is largely derived from mouse models, but its efficacy and safety in humans remain to be established. This review therefore examines whether anthralin can be repurposed as a cutaneous adjuvant for transcutaneous immunization, and which mechanistic and translational constraints must be overcome before human application. - Source: PubMed
Publication date: 2026/07/18
Michael CarolinBros MatthiasRadsak Markus PSchild HansjörgGrabbe Stephan - Research has shown a sex-specific immune response, with males having a worse prognosis in acute inflammatory diseases. While these disparities were initially attributed to sex hormones, increasing evidence points to a predominant role for X-linked genetic factors. Toll-like receptors and several components of their signaling pathway are encoded on the X chromosome and may contribute to these differences. We investigated whether increase in circulating oestradiol influences TLR-dependent immune response. Sixteen women undergoing controlled ovarian hyperstimulation for in vitro fertilisation were studied. Whole blood collected before treatment, during stimulation and at ovulation triggering was stimulated with ligands targeting TLR2/6, TLR1/2, TLR4 and TLR7/8. TLR2, TLR4 and CD99 expression, intracellular phosphorylated NF-κB p65, ERK1/2 and p38 MAPK, and cytokine production were assessed. Oestradiol levels increased markedly during treatment (48.1 to 1819.5 pg/mL; < 0.001). Despite this rise, no or minimal impact on TLR2/4 and CD99 expression, intracellular signalling or cytokine release was detected. Only IL-6 and IL-10 in response to TLR2/6 stimulation increased significantly, with IL-6 positively associated with oestradiol variation. These findings indicate that oestradiol exerts a limited influence on TLR-dependent immune responses, supporting our view that sex-based immune differences are driven primarily by genetic rather than hormonal factors. - Source: PubMed
Publication date: 2026/07/13
Popotas AlexandrosDelbaere AnneCasimir GeorgesCorazza FrancisDe Maertelaer VivianeLefèvre Nicolas - Oral therapy for colorectal cancer (CRC) holds inherent promise for enhancing patient compliance and enabling gastrointestinal targeting, while its application is hampered by low oral drug utilization efficiency and precise colonic localization. This study developes an orally delivered biohybrid complex, CS@CB-Lipo@5-FU/R837, which leverages the hypoxic tropism of the probiotic (CB) for active tumor targeting. The core of the system consists of nanoliposomes co-loaded with 5-fluorouracil (5-FU) and the TLR7 agonist, R837, which are site-specifically anchored to CB via bioorthogonal conjugation. A chitosan-based outer coating ensures gastrointestinal stability and enables enzyme-responsive drug release in the tumor-colonized environment. Within the tumor, the complex orchestrates a coordinated immunotherapeutic cascade: 5-FU induces immunogenic cell death, releasing tumor antigens and damage-associated molecular patterns, while R837 promotes dendritic cell maturation and antigen presentation. This spatiotemporally coupled "antigen-adjuvant' delivery effectively mimics an vaccination mechanism, stimulating potent antitumor immunity. Evaluation in orthotopic and subcutaneous CRC models shows treatment leads to tumor growth inhibition, remodeling of the immune microenvironment, and extended survival. This work establishes a versatile strategy for oral vaccines based on probiotic-guided delivery and localized immune activation. - Source: PubMed
Publication date: 2026/07/14
Fan WenfeiLi ShuaiguangWang XueXu JingyaJiang ShanShen HaixiaYue YanranDong ZhonghuaWang XuanHu HaipingXu Wei - A fundamental constraint of conventional messenger RNA (mRNA) delivery systems is their obligatory trafficking through endosomal-lysosomal compartments, wherein cargo degradation and activation of endosomal Toll-like receptors precipitate substantial translational attrition and deleterious inflammatory cascades. We herein report a chemically engineered platform that circumvents these limitations ab initio. Through strategic perfluoro-acylation of branched polyethyleneimine (PEI, 25 kDa) with pentafluoropropionic anhydride, we install approximately 26 fluoro-amide "zipper" moieties per polymer chain that orchestrate direct, energy-independent trans-bilayer translocation without recruitment of clathrin, caveolae, or lipid raft microdomains-thereby precluding lysosomal entrapment and catabolism. Bio-orthogonal copper-free click chemistry between azide- and dibenzocyclooctyne (DBCO)-terminated PEI-F derivatives, coupled with redox-labile disulfide crosslinkers, engenders polyplexes of exceptional extracellular stability that undergo quantitative glutathione-triggered disassembly within the cytosolic milieu. This endosome-evasive entry mechanism effectively sequesters single-stranded mRNA from Toll-like receptor 3, TLR7, and TLR8 surveillance, establishing a "TLR-attenuated" delivery paradigm characterized by undetectable interferon-α, interferon-β, TNF-α, and IL-6 induction. In human umbilical vein endothelial cells, GFP-mRNA transfection exceeds 90% fluorescent positivity with 4.8-fold superior luciferase expression relative to Lipofectamine™ 3000, whilst maintaining >95% viability. Therapeutic translatability is demonstrated in a murine hindlimb ischemia model, wherein a single 10 μg intramuscular dose of mVEGF-A polyplexes restores blood perfusion to 118% of baseline within 28 days-representing marked superiority over the commercial gold standard and effectuating complete tissue salvage without necrosis. Comprehensive hematological and immunological profiling corroborates the absence of hematotoxicity, systemic inflammation, or innate immune activation. This modular, purely synthetic platform resolves the classical stability-availability paradox whilst eliminating the immunogenic liabilities inherent to endocytic delivery, furnishing a readily translatable scaffold for precision regenerative medicine. - Source: PubMed
Publication date: 2026/07/21
Wang YueXie HaitaoXiang GuoqingLi YanhuaTong ChangguiCui HongyanChen QixianLi HaidongZhao Yan